产品名称 |
Saos-2人成骨肉瘤细胞 |
货号 |
ZQ0447 |
产品介绍 |
Saos-2细胞是一种来源于一名11岁白人女性原发性成骨肉瘤的骨肉瘤细胞系。该病人曾经多种药物治疗,包括RTG.methotrexate,adriamycin vincristine,cytoxan和aramycin-C。该细胞在免疫抑制小鼠中不致瘤,但在半固体培养基中形成集落。该细胞是研究骨肉瘤和骨生物学广泛认可的模型,由于它们的成骨细胞特性和产生骨样细胞外基质的能力。该细胞具有高水平的碱性磷酸酶活性和骨特异性蛋白(如骨钙素和骨桥蛋白)的表达,是研究骨形成和骨肉瘤病理生理的有效体外系统。它对于研究细胞对各种生化刺激和模拟骨环境的机械力的反应特别有价值。
注意事项: 建议用户仔细核对培养基配方和培养条件,每隔2-3天换液一次,并在细胞融合之前进行传代培养,使细胞处于最优的培养条件。 |
种属 |
人 |
性别/年龄 |
女/11岁 |
组织 |
骨 |
疾病 |
骨肉瘤 |
细胞类型 |
肿瘤细胞 |
形态学 |
上皮的 |
生长方式 |
贴壁 |
倍增时间 |
大约35~48小时 |
培养基和添加剂 |
McCoy's 5A基础培养基(品牌:中乔新舟 货号:ZQ-1000)+15%胎牛血清(中乔新舟 货号:ZQ0500)+1%P/S(中乔新舟 货号:CSP006) |
推荐完全培养基货号 |
|
生物安全等级 |
BSL-1 |
STR位点信息 |
Amelogenin: X CSF1PO: 10 D13S317: 12,13 D16S539: 12,13 D5S818: 12 D7S820: 8,10 THO1: 6,9 TPOX: 8 vWA: 18 |
培养条件 |
95%空气,5%二氧化碳;37℃ |
抗原表达/受体表达 |
*** |
基因表达 |
*** |
保藏机构 |
ATCC; CRL-7939 ATCC; HTB-85 DSMZ; ACC-243 ECACC; 89050205 |
供应限制 |
仅供科研使用 |
货号 |
ZQ0447 |
发货规格 |
活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一 |
发货形式 |
活细胞:常温运输;冻存管:干冰运输 |
储存温度 |
活细胞:培养箱;冻存管:液氮罐 |
产地 |
中国 |
供应限制 |
仅供科研使用 |
论文标题: Activation of CXCL6/CXCR1/2 Axis Promotes the Growth and Metastasis of Osteosarcoma Cells in vitro and in vivo
DOI: 10.3389/fphar.2019.00307
发表时间: 2019-03-28
期刊: Frontiers in Pharmacology
影响因子: 5.811
货号: ZQ0447
产品名称: SaOS-2 cell lines
原文链接: https://www.frontiersin.org/articles/10.3389/fphar.2019.00307/full
论文标题: Knockdown of pyruvate kinase type M2 suppresses tumor survival and invasion in osteosarcoma cells both in vitro and in vivo
DOI: 10.1016/j.yexcr.2017.11.020
发表时间: 2017-11-16
期刊: EXPERIMENTAL CELL RESEARCH
影响因子: 3.905
货号: ZQ0447
产品名称: Saos-2 cells
原文链接: https://www.sciencedirect.com/science/article/pii/S0014482717306237
论文标题: Circular RNA circVRK1 suppresses the proliferation, migration and invasion of osteosarcoma cells by regulating zinc finger protein ZNF652 expression via microRNA miR-337-3p
DOI: 10.1080/21655979.2021.1965695
发表时间: 2021-08-23
期刊: Bioengineered
影响因子: 3.269
货号: ZQ0447
产品名称: Saos-2 cells
原文链接: https://www.tandfonline.com/doi/abs/10.1080/21655979.2021.1965695
论文标题: Paeonol antagonizes oncogenesis of osteosarcoma by inhibiting the function of TLR4/MAPK/NF-κB pathway
DOI: 10.1016/j.acthis.2019.151455
发表时间: 2019-10-03
期刊: ACTA HISTOCHEMICA
影响因子: 2.479
货号: ZQ0447
产品名称: Saos-2 cells
原文链接: https://www.sciencedirect.com/science/article/pii/S0065128119301345
论文标题: Effect of lncRNA ANRIL knockdown on proliferation and cisplatin chemoresistance of osteosarcoma cells in vitro
DOI: 10.1016/j.prp.2019.01.042
发表时间: 2019-01-30
期刊: PATHOLOGY RESEARCH AND PRACTICE
影响因子: 1.794
货号: ZQ0447
产品名称: Saos-2 cells
原文链接: https://www.sciencedirect.com/science/article/pii/S0344033818316558
论文标题: MicroRNA‑208a‑3p promotes osteosarcoma progression via targeting PTEN
DOI: 10.3892/etm.2020.9385
发表时间: 2020-10-23
期刊: Experimental and Therapeutic Medicine
影响因子: 1.785
货号: ZQ0447
产品名称: Saos-2 cells
原文链接: https://www.spandidos-publications.com/10.3892/etm.2020.9385
论文标题: MicroRNA-506-3p initiates mesenchymal-to-epithelial transition and suppresses autophagy in osteosarcoma cells by directly targeting SPHK1
DOI: 10.1080/09168451.2019.1569496
发表时间: 2019-01-23
期刊: BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
影响因子: 1.297
货号: ZQ0447
产品名称: SaOS-2 cells
原文链接: https://www.tandfonline.com/doi/abs/10.1080/09168451.2019.1569496
PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)
PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)
PubMed=7017212; DOI=10.1093/jnci/66.6.1003
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
J. Natl. Cancer Inst. 66:1003-1012(1981)
PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)
PubMed=2823272; DOI=10.1073/pnas.84.21.7716
Masuda H., Miller C., Koeffler H.P., Battifora H.A., Cline M.J.
Rearrangement of the p53 gene in human osteogenic sarcomas.
Proc. Natl. Acad. Sci. U.S.A. 84:7716-7719(1987)
PubMed=3040234
Rodan S.B., Imai Y., Thiede M.A., Wesolowski G., Thompson D., Bar-Shavit Z., Shull S., Mann K., Rodan G.A.
Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties.
Cancer Res. 47:4961-4966(1987)
PubMed=2233717; DOI=10.1128/mcb.10.11.5772-5781.1990
Diller L., Kassel J., Nelson C.E., Gryka M.A., Litwak G., Gebhardt M., Bressac B., Ozturk M., Baker S.J., Vogelstein B., Friend S.H.
p53 functions as a cell cycle control protein in osteosarcomas.
Mol. Cell. Biol. 10:5772-5781(1990)
PubMed=8617485; DOI=10.1016/S0046-8177(96)90115-X
Scotlandi K., Serra M., Manara M.C., Benini S., Sarti M., Maurici D., Lollini P.-L., Picci P., Bertoni F., Baldini N.
Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor.
Hum. Pathol. 27:408-416(1996)
PubMed=10763916; DOI=10.1023/A:1006623001465
Jia S.-F., Worth L.L., Kleinerman E.S.
A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies.
Clin. Exp. Metastasis 17:501-506(1999)
PubMed=11416159; DOI=10.1073/pnas.121616198
Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Short tandem repeat profiling provides an international reference standard for human cell lines.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)
PubMed=12645653; DOI=10.1016/S0165-4608(02)00685-4
Ozaki T., Neumann T., Wai D.H., Schaefer K.-L., van Valen F., Lindner N., Scheel C., Boecker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J., Poremba C.
Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping.
Cancer Genet. Cytogenet. 140:145-152(2003)
PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809
Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R., Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B., Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G., Gabbert H.E., Poremba C.
Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3.
Cancer Res. 64:3395-3405(2004)
PubMed=15736406
Pautke C., Schieker M., Tischer T., Kolk A., Neth P., Mutschler W., Milz S.
Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts.
Anticancer Res. 24:3743-3748(2004)
PubMed=15939397; DOI=10.1016/j.bbrc.2005.05.097
Hausser H.-J., Brenner R.E.
Phenotypic instability of Saos-2 cells in long-term culture.
Biochem. Biophys. Res. Commun. 333:216-222(2005)
PubMed=16888811; DOI=10.1002/jcb.21073
Moneo V., Serelde B.G., Fominaya J.M., Martinez-Leal J.F., Blanco-Aparicio C., Romero L., Sanchez-Beato M., Cigudosa J.C., Tercero J.C., Piris M.A., Jimeno J.M., Carnero A.
Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.
J. Cell. Biochem. 100:339-348(2007)
PubMed=17354236; DOI=10.1002/ijc.22643
Muller C.R., Paulsen E.B., Noordhuis P., Pedeutour F., Saeter G., Myklebost O.
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
Int. J. Cancer 121:199-205(2007)
PubMed=17431109; DOI=10.1158/1535-7163.MCT-06-0729
Moneo V., Serelde B.G., Leal J.F.M., Blanco-Aparicio C., Diaz-Uriarte R., Aracil M., Tercero J.C., Jimeno J.M., Carnero A.
Levels of p27(kip1) determine Aplidin sensitivity.
Mol. Cancer Ther. 6:1310-1316(2007)
PubMed=17981215; DOI=10.1016/j.cancergencyto.2007.08.003
Selvarajah S., Yoshimoto M., Maire G., Paderova J., Bayani J., Squire J.A., Zielenska M.
Identification of cryptic microaberrations in osteosarcoma by high-definition oligonucleotide array comparative genomic hybridization.
Cancer Genet. Cytogenet. 179:52-61(2007)
PubMed=19787792; DOI=10.1002/gcc.20717
Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E., Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H., Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W., Buerger H., Aigner T., Gabbert H.E., Poremba C.
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.
Genes Chromosomes Cancer 49:40-51(2010)
PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=21519327; DOI=10.1038/labinvest.2011.72
Mohseny A.B., Machado I., Cai Y.-P., Schaefer K.-L., Serra M., Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.
Functional characterization of osteosarcoma cell lines provides representative models to study the human disease.
Lab. Invest. 91:1195-1205(2011)
PubMed=22075555; DOI=10.1158/0008-5472.CAN-11-2778
Huang G.-X., Yu L., Cooper L.J.N., Hollomon M., Huls H., Kleinerman E.S.
Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases.
Cancer Res. 72:271-281(2012)
PubMed=23144859; DOI=10.1371/journal.pone.0048262
Kresse S.H., Rydbeck H., Skarn M., Namlos H.M., Barragan-Polania A.H., Cleton-Jansen A.-M., Serra M., Liestol K., Hogendoorn P.C.W., Hovig E., Myklebost O., Meza-Zepeda L.A.
Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma.
PLoS ONE 7:E48262-E48262(2012)
PubMed=23671654; DOI=10.1371/journal.pone.0063056
Lu Y.-H., Soong T.D., Elemento O.
A novel approach for characterizing microsatellite instability in cancer cells.
PLoS ONE 8:E63056-E63056(2013)
货号 | 产品名称 | 规格 | 价格 | 指令 |
ZQ505-K | 支原体检测试剂盒 | 1ml/100T | ¥800.00 | 放入购物车 》 |
ZQ506 | 支原体清除试剂盒 | 1ml | ¥600.00 | 放入购物车 》 |
A1001-1 | 国产转染试剂 | 1ml | ¥800.00 | 放入购物车 》 |
1 | 慢病毒介导基因沉默或过表达 | ¥询价 | 放入购物车 》 | |
5 | 荧光素酶标记 | ¥询价 | 放入购物车 》 | |
6 | 绿/红色荧光蛋白标记 | ¥询价 | 放入购物车 》 | |
ZQ-100 | DMEM(高糖)基础培养基 | 500ml | ¥56.00 | 放入购物车 》 |
ZQ-101 | DMEM(高糖)完全培养基 | 500ML | ¥350.00 | 放入购物车 》 |
ZQ500-A | 优级胎牛血清 | 500ml | ¥2580(开学促销) | 放入购物车 》 |
0563 | 支原体抑制剂 10 mg/ml; 1 ml(定制) | 10 mg/ml; 10 x 1 ml | ¥1808.00 | 放入购物车 》 |
JSFW-134 | 人源细胞STR鉴定服务 | ¥900.00 | 放入购物车 》 |